Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases.The term was introduced in the inaugural Editorial,Introducing Oncotarget.
As of January 1, 2022,Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
SSP 47th Annual Meeting
Post-Publication Promotion
Learn about ourFREE
Impact Journals, LLC is the publisher of Oncotarget:www.impactjournals.com.
Impact Journals is a member of theWellcome Trust List of Compliant Publishers.
Impact Journals is a member of theSociety for Scholarly Publishing.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.This malicious action will be reported to the FBI.
Current Volume
This Month's Popular DOIs
(Crossref resolutions)
| 10.18632/ONCOTARGET.23208 |
| 10.18632/ONCOTARGET.6429 |
| 10.18632/ONCOTARGET.9859 |
| 10.18632/ONCOTARGET.13553 |
| 10.18632/ONCOTARGET.14401 |
| 10.18632/ONCOTARGET.15422 |
| 10.18632/ONCOTARGET.16407 |
| 10.18632/ONCOTARGET.19087 |
Most popular Oncotarget DOIs, measured by the number of times each DOI was successfully resolved.
Most Popular DOIs Published in 2024
(Crossref Data)
Top-10 Most Popular DOIs of 2024
(Crossref Data)
Milestones in Modern Scholarly Publishing
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025.Learn more here andhere.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds.Learn more.
Oncotarget.org: Blog Posts on
New & Trending Papers
Oncotarget.net: Latest Insights
From Our Authors
October 16, 2018
About The Cover
The cover for issue 81 of Oncotarget features Figure 1, "Molecular Mechanisms of Autophagy," byServante, et al.
Table of Contents
News
| V-ATPase in cancer progression: Two sides of the same coin |
https://doi.org/10.18632/oncotarget.26218 Mohd Saqib, and Bibhuti B. Mishra |
| 35197-35198 |
| PDF | How to cite |
| Clinical application of cfDNA: moving in the right direction, but still a long way to go |
https://doi.org/10.18632/oncotarget.26224 Shehara Mendis, and Jonathan M. Loree |
| 35199-35200 |
| PDF | How to cite |
Editorial
| Mutant molecular chaperone activates cytokine receptor as a homomultimer |
https://doi.org/10.18632/oncotarget.26221 Marito Araki, and Norio Komatsu |
| 35201-35202 |
| PDF | How to cite |
| ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells |
https://doi.org/10.18632/oncotarget.26230 Daichi Inoue,Takeshi Fujino, and Toshio Kitamura |
| 35203-35204 |
| PDF | How to cite |
| Rise of the specialized onco-ribosomes |
https://doi.org/10.18632/oncotarget.26231 Kim R. Kampen,Sergey O. Sulima, and Kim De Keersmaecker |
| 35205-35206 |
| PDF | How to cite |
Research Papers
| Biothiols and oxidative stress markers and polymorphisms ofTOMM40 andAPOC1 genes in Alzheimer's disease patients |
https://doi.org/10.18632/oncotarget.26184 Michal Prendecki,Jolanta Florczak-Wyspianska,Marta Kowalska,Jan Ilkowski,Teresa Grzelak,Katarzyna Bialas,Malgorzata Wiszniewska,Wojciech Kozubski, and Jolanta Dorszewska |
| 35207-35225 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
https://doi.org/10.18632/oncotarget.26215 Sunkyu Kim,Ralph Tiedt,Alice Loo,Thomas Horn,Scott Delach,Steven Kovats,Kristy Haas,Barbara Schacher Engstler,Alexander Cao,Maria Pinzon-Ortiz,Iain Mulford,Michael G. Acker,Rajiv Chopra,Christopher Brain,Emmanuelle di Tomaso,William R. Sellers, and Giordano Caponigro |
| 35226-35240 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state |
https://doi.org/10.18632/oncotarget.26235 Elena V. Skvortsova,Sergey A. Sinenko, and Alexey N. Tomilin |
| 35241-35250 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
Clinical Research Papers
| Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors |
https://doi.org/10.18632/oncotarget.25834 Alessandro Ottaiano,Valerio Scotti,Chiara De Divitiis,Monica Capozzi,Carmen Romano,Antonino Cassata,Rossana Casaretti,Lucrezia Silvestro,Anna Nappi,Valeria Vicario,Alfonso De Stefano,Salvatore Tafuto,Massimiliano Berretta,Guglielmo Nasti, and Antonio Avallone |
| 35251-35265 |
| Abstract | PDF | HTML | How to cite |
Reviews
| Chemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors |
https://doi.org/10.18632/oncotarget.26186 Juliette Servante,Jasper Estranero,Lisethe Meijer,Rob Layfield, and Richard Grundy |
| 35266-35277 |
| Abstract | PDF | HTML | How to cite | Press Release |
Case Reports
| ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report |
https://doi.org/10.18632/oncotarget.26233 Masaya Taniwaki,Masahiro Yamasaki,Koto Kawata,Kazuma Kawamoto,Kunihiko Funaishi,Yu Matsumoto,Naoko Matsumoto,Nobuyuki Ohashi, and Noboru Hattori |
| 35278-35282 |
| Abstract | PDF | HTML | How to cite |
Corrections
| Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor |
https://doi.org/10.18632/oncotarget.26252 Zexi Hu,Yong Hu,Xicheng Liu,Rongwen Xi,Aiqun Zhang,Deruo Liu,Qiang Xie, and Liang Chen |
| 35283-35283 |
| Correction | PDF | How to cite |
| Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer |
https://doi.org/10.18632/oncotarget.26254 Naiqing Xu,Wenfeng Fang,Libing Mu,Yanna Tang,Lei Gao,Shengxiang Ren,Dengfeng Cao,Lixin Zhou,Aiqun Zhang,Deruo Liu,Caicun Zhou,Kwok-Kin Wong,Lei Yu,Li Zhang, and Liang Chen |
| 35284-35284 |
| Correction | PDF | How to cite |
| Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment |
https://doi.org/10.18632/oncotarget.26255 Hongjuan Zhang,Cheng Zhan,Ji Ke,Zhiqiang Xue,Aiqun Zhang,Kaifeng Xu,Zhirong Shen,Lei Yu, and Liang Chen |
| 35285-35285 |
| Correction | PDF | How to cite |
Errata
| Erratum: Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity |
https://doi.org/10.18632/oncotarget.26258 Kelly K. Haagenson,Jessica Wei Zhang,Zhengfan Xu,Malathy P.V. Shekhar, and Gen Sheng Wu |
| 35286-35286 |
| Erratum | PDF | How to cite |
Copyright © 2025 Rapamycin Press LLC dba Impact Journals